A new therapeutic approach for atopic dermatitis is being developed, utilizing a dual mechanism that targets barrier repair through KLK5/7 and inflammation inhibition through IL-13. This first-in-class treatment aims to address the needs of patients with atopic dermatitis. A Phase 2 patient proof-of-concept study focusing on moderate-to-severe cases of atopic dermatitis is planned to commence soon. This study will test the effectiveness of the treatment and its potential benefits for patients.